Wendy Cheng

Dr. Wendy Cheng specializes in health economics and outcomes research (HEOR) and epidemiology to develop strategies for product development, differentiation, and access; and to implement analytic methods to generate real-world evidence to demonstrate unmet needs, comparative effectiveness, and long-term safety of therapeutic products. Dr. Cheng also provides expert support and testimony in disputes that require the analysis of clinical data. Her experience includes natural history studies, economic and predictive modeling, real-world evidence development, surveys, individualized medicine, patient decision aids, and post-approval and -authorization safety studies for the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Her work spans multiple therapeutic areas, including rare and ultra-rare diseases.

Dr. Cheng also specializes in applying advanced methodologies to address complex healthcare research challenges. She has used machine learning and other predictive modeling techniques, including latent class analysis to identify cost clusters in disease patient population, group-based trajectory analysis to identify disease prognosis patterns, and rule-based approaches to diagnostic algorithms. Dr. Cheng has collected and utilized data from clinical trials, administrative insurance claims, electronic medical records, site- and panel-based medical chart reviews, patient registries, large patient and physician surveys, and longitudinal observational studies. She has conducted studies in more than ten countries and published her research in numerous medical journals.

Prior to her career in healthcare consulting, Dr. Cheng served as a research scientist at Columbia University and worked as a biostatistician in the Clinical Trials Network of the National Institute on Drug Abuse.